<DOC>
	<DOCNO>NCT02297438</DOCNO>
	<brief_summary>The study design compare clinical benefit follow treatment letrozole combination Palbociclib versus letrozole combination placebo Asian postmenopausal woman ER ( + ) /HER2 ( - ) advance breast cancer receive prior systemic anti cancer therapies advanced/metastatic disease .</brief_summary>
	<brief_title>A Study Of Palbociclib ( PD-0332991 ) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer PALOMA-4</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Adult Asian woman locoregionally recurrent metastatic disease amenable curative therapy Confirmed diagnosis ER positive breast cancer No prior systemic anticancer therapy advance ER+ disease Postmenopausal woman Measurable disease per Response Evaluation Criterion Solid Tumors [ RECIST ] boneonly disease Eastern Cooperative Oncology Group [ ECOG ] 01 Adequate organ marrow function Patient must agree provide tumor tissue Confirmed diagnosis HER2 positive disease Patients advance , symptomatic , visceral spread risk life threaten complication short term Known uncontrolled symptomatic CNS metastases Prior neoadjuvant adjuvant treatment non steroidal aromatase inhibitor ( ie , anastrozole letrozole ) disease recurrence within 12 month complete treatment Prior treatment CDK 4/6 inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>estrogen-receptor positive</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>locoregionally recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>